Get Updates

Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Research & Clinical Trials > Study Search Tool > A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

| More

A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

This study is open to:

Men with advanced prostate cancer who:

  • have a known gene mutation in BRCA1, BRCA2 or ATM will be eligible.
  • must have undergone surgical or medical castration (testosterone ≤ 50 ng/dL )
  • have had their disease progress after receiving one of the following treatments for castration-resistant disease: "next-generation androgen receptor-targeted therapies": Enzalutamide, also known as Xtandi or Abiraterone, also known Zytiga).
This study is not open to:

Patients will be excluded if they have:

  • received prior treatment with chemotherapy for metastatic castration-resistant prostate cancer

  • prior treatment with a PARP inhibitor, mitoxantrone, cyclophosphamide or platinum-based chemotherapy

  • any active second cancer diagnosis, with the exception of non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer

  • symptomatic and/or untreated central nervous system metastases
A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer

Clinicaltrials.gov identifier:
NCT02975934

Treatment:
Prostate

Study Contact Information

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email  

The study is open and recruiting at sites in CA, FL, GA, HI, MD, NE, NV, NJ, NY, NC, OH, TN, TX, VA.

About the Study

The purpose of Triton3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited gene mutation or tumor genetic deficiency respond to treatment with the PARP inhibitor rucaparib (Rubraca) compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Type of Study

This is a randomized, open-label, 2-arm study. This study allows crossover. 

  • This is a randomized study, which means that participants will be placed into one of the two treatment groups by chance. Neither patients nor the research doctor will choose the group participants are placed in. This is a 2:1 randomized study. This means that patients will have a slightly greater chance of being placed in the treatment group than the standard treatment group. 
  • The study has two arms. This means that patients in the study are placed in one of two different groups. One group will received the PARP inhibitor rucaparib and the other group will receive one of three standard treatment options chosen by their oncologist. 
  • The study is open-label. All participating patients will know which group they have been assigned to. 
  • The study allows crossover. This means that patients who progress on the standard treatment arm will be given the opportunity to crossover into the rucaparib arm if they choose. 

What Study Entails

  • Patients with a known gene mutation in BRCA1, BRCA2 or ATM will be eligible. 
  • Patients will receive the oral PARP inhibitor Rucaparib (Rubraca) twice daily for 28 days.
  • Patients will receive followup at 28 days.
  • Patients will receive assessments every 12 weeks.  
  • Patients who receive clinical benefit from the drug may be considered for continued treatment even if their cancer has progressed. 
  • Patients receiving rucaparib whose cancer progresses will be taken off the study agent. 
  • Patients who progress on the standard treatment arm will be given the opportunity to crossover into the rucaparib arm if they choose.

Study Sites

  • California
    • San Bernardino
    • San Diego
    • Santa Rosa
  • Florida
    • Orlando
  • Georgia
    • Atlanta
  • Hawaii
    • Honolulu
  • Maryland
    • Baltimore
  • Nebraska
    • Omaha
  • Nevada
    • Las Vegas
  • New Jersey
    • Township
  • New York
    • Poughkeepsie
  • North Carolina
    • Concord
  • Ohio
    • Cincinnati
    • Middleburg Heights
  • Tennessee
    • Nashville
  • Texas
    • Dallas
  • Virginia
    • Virginia Beach

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email  

The study is open and recruiting at 21 sites, most in the US. 

United States Sites:

FORCE:Facing Our Risk of Cancer Empowered